BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its position in Agilent Technologies, Inc. (NYSE:A) by 83.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 331,920 shares of the medical research company’s stock after buying an additional 150,969 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned 0.10% of Agilent Technologies worth $21,309,000 at the end of the most recent reporting period.
Several other hedge funds have also recently modified their holdings of the business. Dupont Capital Management Corp acquired a new position in Agilent Technologies during the 3rd quarter valued at about $101,000. Balentine LLC increased its holdings in shares of Agilent Technologies by 2.9% in the second quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock valued at $106,000 after purchasing an additional 50 shares during the period. Sun Life Financial INC increased its holdings in shares of Agilent Technologies by 26,144.4% in the second quarter. Sun Life Financial INC now owns 2,362 shares of the medical research company’s stock valued at $140,000 after purchasing an additional 2,353 shares during the period. Acrospire Investment Management LLC increased its holdings in shares of Agilent Technologies by 92.3% in the second quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock valued at $148,000 after purchasing an additional 1,200 shares during the period. Finally, Parallel Advisors LLC increased its holdings in shares of Agilent Technologies by 5.3% in the second quarter. Parallel Advisors LLC now owns 2,623 shares of the medical research company’s stock valued at $157,000 after purchasing an additional 131 shares during the period.
A number of brokerages have recently commented on A. Robert W. Baird restated a “buy” rating and issued a $70.00 target price on shares of Agilent Technologies in a research note on Friday, October 20th. Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $74.00 price target on the stock in a research report on Tuesday, October 10th. Barclays increased their price target on Agilent Technologies from $67.00 to $71.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 21st. Morgan Stanley reiterated an “overweight” rating on shares of Agilent Technologies in a research report on Tuesday, November 14th. Finally, Deutsche Bank set a $75.00 target price on Agilent Technologies and gave the company a “buy” rating in a report on Tuesday, November 21st. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $68.34.
Agilent Technologies, Inc. (A) opened at $67.61 on Friday. The stock has a market capitalization of $21,404.78, a price-to-earnings ratio of 28.06, a P/E/G ratio of 2.01 and a beta of 1.27. Agilent Technologies, Inc. has a fifty-two week low of $45.36 and a fifty-two week high of $70.93. The company has a quick ratio of 2.85, a current ratio of 3.30 and a debt-to-equity ratio of 0.37.
Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Monday, November 20th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.05. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. Agilent Technologies had a return on equity of 16.96% and a net margin of 15.30%. Agilent Technologies’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.59 EPS. research analysts anticipate that Agilent Technologies, Inc. will post 2.58 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 24th. Stockholders of record on Tuesday, January 2nd will be given a dividend of $0.149 per share. The ex-dividend date of this dividend is Friday, December 29th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.88%. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.13. Agilent Technologies’s payout ratio is 25.24%.
In other Agilent Technologies news, SVP Jacob Thaysen sold 22,583 shares of Agilent Technologies stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $70.41, for a total value of $1,590,069.03. Following the sale, the senior vice president now owns 63,042 shares of the company’s stock, valued at approximately $4,438,787.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Mark Doak sold 4,154 shares of the business’s stock in a transaction that occurred on Tuesday, December 5th. The stock was sold at an average price of $67.00, for a total value of $278,318.00. Following the sale, the vice president now directly owns 68,270 shares in the company, valued at approximately $4,574,090. The disclosure for this sale can be found here. Insiders have sold 117,021 shares of company stock worth $8,128,154 in the last quarter.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2017/12/16/agilent-technologies-inc-a-shares-bought-by-british-columbia-investment-management-corp.html.
Agilent Technologies Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.